Barely a week passes without someone arriving who had an executive checkup last year. They bring a folder of several dozen pages — a day of specialist consultations, a broad blood panel, imaging, a stress test — ending in a reassuring line: everything within the normal range. Usually that is true. But the question that brought them to us went unanswered, because it was never asked. They came not to learn whether something is broken today, but where they are heading, and what to do over the next decade to change direction.
This is not a criticism of execution. The Israeli executive screening is generally thorough, professional and well organised, and it finds real problems in real people. It is built to answer one question — is there disease here that needs treating now — not the second. That difference, and what falls between the two, is the subject of this article.
What an executive checkup includes, and what it genuinely delivers
The format is familiar. One day, usually at a private medical centre or a dedicated hospital unit: a physical examination; consultations across cardiology, gastroenterology, urology or gynaecology, ophthalmology, dermatology and ENT; a broad blood panel and urinalysis; an ECG and stress test; sometimes echocardiography, abdominal ultrasound, spirometry, vision and hearing tests, and cancer screening by age and sex. It is paid for by an employer, out of pocket, or partly subsidised through supplementary insurance (bituach mashlim) from the health funds (kupot holim) — to an extent that varies between funds, plans and providers, so it is worth checking in advance what is covered and what costs extra.
What does it deliver? Three things worth respecting. Breadth: a panel covering kidney and liver function, thyroid, blood count, lipids and glucose will pick up anaemia, hypothyroidism or an early fall in renal function — and the examination will record a blood pressure nobody has taken in years. Convenience: what might otherwise be spread across months of referrals and waiting is compressed into one day. Completion — and this is the most important of the three. A common failure in preventive medicine is not choosing the wrong test but never performing the right one, year after year. An executive checkup solves that in one morning.
So it should be said plainly: for a healthy person in their forties, with no unusual family history, no previous findings and no accumulating risk factors, this is often exactly the right level. If that is you, there is little point reading on. Go and book one.
An executive checkup is a high-quality still photograph. Preventive medicine is concerned with motion — and motion does not appear in a single image, however sharp.
A snapshot, not a trajectory
This is the first gap, and the most structural of them all. Fasting glucose of 84 at forty-two, 91 at forty-seven, 97 at fifty-two. Every result is normal, every report reassuring on its own. The sequence tells a different story — a steady climb inside the normal range towards its upper edge, across three encounters at which nobody saw it, because nobody put the three side by side.
The same happens to an eGFR drifting down, an HbA1c travelling from 5.2 to 5.7, a ferritin creeping up, a weight rising a kilogram a year. A marker moving within the normal range across a decade is exactly what preventive medicine should catch first, and exactly what vanishes when each test is read as a standalone event. The information almost always exists already — in your health fund record, on the portal, in last year's PDF. What is missing is not a data point, but someone to lay the data on a timeline and ask where the line leads.
"Within the normal range" answers a different question
The reference range printed beside every result is built, broadly speaking, from the distribution of results in a reference population tested at that laboratory — usually its wide middle, with both extremes removed. The implication is simple, and not always spelled out: "normal" means "typical for the people tested here", not "optimal for you". In a population where excess weight, prediabetes and prolonged sitting are common, the average is not a particularly ambitious target.
Then there is continuity. Cardiovascular risk does not jump at a threshold; it rises continuously with particle number, with blood pressure, with glucose. The line drawn in the laboratory is an administrative decision to simplify reporting, not a biological boundary. In fairness, the opposite deserves saying as well: not every marker has an "optimal target" demonstrated in an interventional trial. LDL-C has well-established targets by risk level, ApoB has parallel targets in the guidelines, blood pressure has them. Much of what is sold today as "optimal" rests on an educated estimate and nothing more. Telling the two apart is part of the work, and not every clinic bothers.
The lipid panel measures quantity, not particle number
Every executive checkup includes a lipid panel, and it almost always reports LDL-C — the quantity of cholesterol carried inside LDL particles. But atherosclerosis is not driven directly by that quantity; it is driven by the number of particles containing apolipoprotein B that enter the arterial wall and are retained there. ApoB counts the particles themselves, and in a substantial minority the two measures disagree — particularly when triglycerides are high or metabolic syndrome is present. In them an apparently normal LDL-C can conceal a high particle burden.
A second gap, simple to close: Lp(a). Its level is almost entirely genetic, barely changes over a lifetime, and is elevated in about a fifth of the population. It is absent from the standard panel, once in a lifetime is enough, and the result shifts the threshold for intervening on every other risk factor. Someone with a high Lp(a) told their lipids were normal received a correct answer to a partial question.
| The clinical question | What is usually measured | What answers it more precisely |
|---|---|---|
| How many atherogenic particles the blood carries | LDL-C | ApoB |
| Is there hidden genetic risk | Usually not measured | Lp(a), once in a lifetime |
| Is there already plaque in the artery | Usually not measured | CIMT or coronary calcium (CAC) |
| When did insulin resistance begin | Fasting glucose, HbA1c | Fasting insulin, HOMA-IR |
| How glucose behaves day to day | A single fasting time point | CGM for two weeks |
| What the cardiorespiratory fitness is | Stress test, to detect ischaemia | Measured VO₂max |
| What the muscle mass and strength are | Weight and BMI | DEXA, grip strength |
| Where the fat accumulates | Waist circumference | Visceral fat on imaging |
Fasting glucose and HbA1c are the late signals
A normal fasting glucose is usually read as a certificate of metabolic good character. Physiology is less generous. The pancreas can compensate for falling insulin sensitivity for years, holding glucose entirely normal — at the price of secreting more and more insulin. Glucose rises only once that compensation begins to fail. Fasting insulin and HOMA-IR therefore describe the process earlier, and continuous glucose monitoring in someone without diabetes shows what a single fasting point cannot: how high the rise after a real meal goes, how long it lasts, and what sleep and activity do to it.
The fair caveat: insulin assays are not well standardised between laboratories, and no threshold is universally agreed. CGM in healthy people still has no outcome trials showing reduced disease. Both are good early markers and good drivers of behavioural change — not diagnoses. Anyone selling them as diagnoses is selling more than exists.
Functional capacity is almost never measured
Cardiorespiratory fitness is among the strongest predictors of all-cause mortality and of years lived in independent function — stronger than most of the risk factors measured on the day. Yet it is almost never reported as a metric. A stress test is performed, but read mainly to exclude ischaemia rather than to quantify capacity: usually stopped at the target heart rate rather than at maximal effort, and summarised as "normal" rather than as a number you can follow. Measured VO₂max is a different number altogether — improvable, trackable, and of practical relevance to what your seventies look like.
The same logic applies to muscle. Weight and BMI do not distinguish muscle from fat and say nothing about where the fat sits. Grip strength, muscle mass and visceral fat on imaging give a completely different — and often more troubling — picture in people whose weight is "normal".
No single doctor holds the whole picture
This, in our view, is the most consequential gap, and it is organisational rather than technological. On the day you met six specialists. Each looked at their own organ, wrote a paragraph, sometimes added a recommendation to follow something up. None saw the other five paragraphs before writing their own, and none is responsible for what happens tomorrow. The synthesis — what it all means together, what takes priority, what actually has to change — is left with you.
Then comes the following day. You arrive at your family doctor with a file dozens of pages long and a short appointment. They did not order the tests, did not see you with the consultants, and sometimes cannot even open the file on their system. Recommendations that required a decision become "we will keep an eye on it next year", and often there is no next year. A year or two later a new checkup comes round, with a different provider, starting from zero. That is the real difference between a comprehensive assessment and a programme that has an owner: not the list of tests, but who holds the picture and who is accountable for what follows.
Who should go deeper, and what to ask for
Most people need nothing more than the conventional route. Some do, usually for a defined reason rather than a general feeling. Going further is worth considering if one of these applies to you:
- A cardiac event or stroke in the family at a young age — under fifty-five in a man, sixty-five in a woman
- Results moving consistently in one direction over years, even when each one is "normal"
- High triglycerides, a widening waist, or prediabetes diagnosed and never treated
- A previous checkup that produced an unexplained finding with no real follow-up
- Regular use of several medications, or an unusual reaction to a drug in the past
- Fifty and over, with a genuine intention to invest in the coming decade rather than merely monitor it
And whichever provider you choose — a private clinic, a hospital, or us — these are the requests worth bringing with you. All are legitimate, most are relatively inexpensive, and any serious provider will know how to respond to them:
- Add ApoB to the lipid panel, and Lp(a) once. Two simple blood tests that reshape the cardiovascular risk map more than the rest of the panel combined.
- Ask for fasting insulin alongside the glucose. The gap between the two is usually the earliest information you will get about your metabolic direction.
- Ask for a number, not "normal". And above all, ask to see the result next to your results from previous years rather than on its own.
- Ask that fitness be measured and recorded. VO₂max, grip strength, body composition — measures you can improve, unlike age.
- Ask who is responsible for what follows. Who reads the whole report, who decides what comes first, and when exactly the next appointment is.
A good executive checkup does exactly what it promises: it establishes that no disease requires treatment right now, thoroughly and in a single day. That is worth something, and sometimes a great deal. It simply was not designed to answer the second question — where your markers are moving, what that means for the next decade, and who is accountable for changing course. If that is your question, it is worth asking explicitly, of someone whose job is to answer it. You are welcome to arrange a conversation and find out whether that is in fact your question.